Search results
Author(s):
Marco Schiavone
,
Claudio Tondo
Added:
2 months ago
Dr Marco Schiavone (Centro Cardiologico Monzino IRCCS, Milan, IT) and Dr Claudio Tondo (Monzino Cardiologic Centre, Milan, IT) discuss long-term durability data from an 8-year follow-up study of cryoballoon pulmonary vein isolation for atrial fibrillation.In this Journal Club session, the experts dig into real-world evidence on the extended durability of cryoballoon ablation, tackling key…
View more
Author(s):
Nadira Hamid
,
Rahul P Sharma
Added:
6 months ago
TCT 2025 — Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr Rahul P Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease.The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and…
View more
Author(s):
Martin Swaans
,
Vijay Kunadian
,
,
et al
Added:
2 years ago
In this on-demand version of the live broadcast, chaired by Dr Martin Swaans (St Antonius Hospital, NL), faculty explore the evolving data for transcatheter aortic valve implantation (TAVI) and why we need to improve triaging practices towards the most appropriate interventions.Leading experts, Prof Sabine Bleiziffer (Heart and Diabetes Center NRW, DE), Prof Vijay Kunadian (Newcastle University,…
View more
Added:
2 months ago
Source:
Transcatheter Academy
Seven-year follow-up data from the PARTNER 3 trial shows no significant difference in key outcomes between transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement (SAVR) for low-risk patients with severe, symptomatic aortic stenosis.¹ This long-term assessment provides further insight into valve durability and clinical outcomes, building on previous 5-year data which…
View more
Aditi Balakrishna
Job title: Assistant Professor of Anesthesiology, Division of Critical Care
Author
Innovation and Development of PHV TAVR
Author(s):
Yu Mao
,
Fengkai Liu
,
Xi Chen
,
et al
Added:
6 months ago
Review Article
Author(s):
Luigi Di Biase
Added:
2 years ago
EHRA 2024 — Dr Luigi Di Biase (Albert Einstein College of Medicine and Montefiore Medical Center, US) highlights 3 late-breaking trials from the 2024 EHRA scientific sessions. Discover the trials anticipated to reshape clinical practice as Dr Di Biase shares his insights.Trials discussed in detail include:00:36 - Novel Conformable "Single-Shot" PFA Catheter for Pulmonary Vein Isolation01:08 -…
View more
Author(s):
Tina Baykaner
,
Added:
3 months ago
AF Symposium 2026 - Pulsed field ablation in atrial fibrillation: Will it Redefine AF Ablation Strategies?Arrhythmia Academy board member Dr Tina Baykaner (Stanford University, Stanford, CA, US) is joined by Dr Melanie Gunawardene (CCB Frankfurt und Main-Taunus, Frankfurt, DE) exploring whether pulsed field ablation will fundamentally transform atrial fibrillation ablation strategies in 2026.This…
View more
Author(s):
Boris Schmidt
Added:
2 years ago
EHRA 24 - Investigator, Dr Boris Schmidt (Cardioangiologisches Centrum Bethanien, DE) is interviewed on ablation strategies for repeat procedures in patients with recurrent atrial fibrillation (AF).The ASTRO trial is a multi-centre prospective randomized study that enrolled 256 patients with drug-refractory AF despite previous AF ablation. The trial showed no statistically significant differences…
View more
Author(s):
Patrick W Serruys
Added:
12 months ago
EuroPCR 25 - Novel Myval THV shows non-inferiority at one year compared to established valves in severe aortic stenosis.We are joined by Dr Patrick Serruys (Erasmus University Medical Center, Rotterdam, NL) to discuss key findings from the LANDMARK trial.This multinational, multicentric, randomized controlled trial compared the safety and effectiveness of the Myval THV Series against contemporary…
View more